Laudone Thomas W, Garner Lauren, Kam Charissa W, Esther Charles R, McKinzie Cameron J
Department of Pharmacy, University of North Carolina Medical Center, Chapel Hill, North Carolina.
Division of Pediatric Pulmonology, Department of Pediatrics, University of North Carolina School of Medicine, Chapel Hill, North Carolina.
Pediatr Pulmonol. 2021 Feb;56 Suppl 1:S55-S68. doi: 10.1002/ppul.24939.
Respiratory infections caused by non-tuberculous mycobacteria (NTM) are a major cause of morbidity for patients living with cystic fibrosis (CF), as NTM pulmonary disease (NTM-PD) is challenging to both diagnose and eradicate. Despite the lengthy courses of the established regimens recommended by the Cystic Fibrosis Foundation (CFF) and European Cystic Fibrosis Society (ECFS) consensus guidelines, only about 50% to 60% of patients achieve culture conversion, and treatment regimens are often complicated by antibiotic resistance and toxicities. Since publication of the CFF/ECFS guidelines, several new or alternative antibiotic regimens have been described for patients with CF who have NTM-PD. These regimens offer new options for patients who do not clear NTM with standard therapies or cannot utilize the usual regimens due to toxicities or drug-drug interactions.
非结核分枝杆菌（NTM）引起的呼吸道感染是囊性纤维化（CF）患者发病的主要原因，因为NTM肺病（NTM-PD）的诊断和根除都具有挑战性。尽管囊性纤维化基金会（CFF）和欧洲囊性纤维化协会（ECFS）共识指南推荐的既定治疗方案疗程漫长，但只有约50%至60%的患者实现培养转阴，且治疗方案常因抗生素耐药性和毒性而变得复杂。自CFF/ECFS指南发布以来，已针对患有NTM-PD的CF患者描述了几种新的或替代抗生素治疗方案。这些方案为那些采用标准疗法无法清除NTM或因毒性或药物相互作用而无法使用常规方案的患者提供了新的选择。
